Table 1.

Patient characteristics at first clinical in-stent restenosis presentation

Parameter	DM group (n=109)	Non-DM group (n=82)	P-value
Demographics
Age	60.7±9.3	61.8±10.8	0.464
Men	90 (82.6%)	65 (79.3%)	0.564
BMI	23.3±3.7	23.6±3.1	0.690
Clinical characteristics
Hypertension#	66 (60.6%)	38 (46.3%)	0.050
Chronic kidney disease	12 (11.0%)	9 (11.0%)	0.994
Acute kidney injury	20 (18.3%)	12 (14.6%)	0.496
Dyslipidemia*	61 (74.4%)	37 (57.8%)	0.034
Current tobacco use	21 (19.3%)	18 (22.0%)	0.649
CCF	21 (19.3%)	13 (15.9%)	0.542
NYHA 3, 4	9 (8.3%)	11 (13.4%)	0.249
LVEF	52.0±11.1	53.5±10.3	0.325
Previous MI	57 (52.3%)	43 (52.4%)	0.984
Previous CABG	10 (9.2%)	4 (4.9%)	0.259
Statin therapy	96 (88.1%)	67 (81.7%)	0.218
Clinical presentation
Non-ACS	41 (37.6%)	32 (39.0%)	0.843
ACS	68 (62.4%)	50 (61.0%)
Unstable angina	30 (27.5%)	22 (26.8%)
MI	38 (34.9%)	28 (34.1%)
NSTEMI	30 (27.5%)	22 (26.8%)
STEMI	8 (7.3%)	6 (7.3%)
Silent ischemia	14 (12.9%)	8 (9.8%)	0.398
Lab parameters
HbA1c	8.2±1.4	5.8±0.4	<0.001
FBS	176±70	104±20	<0.001
Lipid profile* (mg/dL)
Total cholesterol	143±44	148±39	0.450
LDL	78±37	83±33	0.437
HDL	38±11	42±12	0.063
Triglycerides	139±75	119±64	0.088

^*Dyslipidemia defined as total cholesterol >250 mg/dL, LDL cholesterol >130 mg/dL, HDL cholesterol <40 mg/dL (<50 mg/dL for women) in the fasting state. Data available for 146 patients.

^#Blood pressure >140/90 mm Hg or the use of antihypertensive therapy. ACS - acute coronary syndrome; BMI - body mass index; CABG - coronary artery bypass grafting; CCF - congestive cardiac failure; HbA1c - glycosylated hemoglobin; LVEF - left ventricular ejection fraction; LDL - low-density lipoprotein;

HDL - high-density lipoprotein; MI - myocardial infarction; NYHA - New York Heart Association